Myocardial Revascularization

5

Review clinical trials related to Myocardial Revascularization. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization

1. Evaluate the efficacy and safety of Qidan Xiaohe granules in patients after coronary revascularization surgery; 2. Develop a traditional Chinese medicine rehabilitation treatment plan and evaluation system for the use of Qidan Xiaohe granules after coronary revascularization surgery; 3. Demonstrate the advantages of traditional Chinese medicine rehabilitation treatment in the postoperative management of coronary revascularization surgery and provide high-level evidence-based medical evidence for the development of traditional Chinese medicine rehabilitation treatment plans.

Participants needed: 164
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Liu QiangUpdated: Jun 1, 2026
Eligibility criteria

Age: 18-80 years old; [+4]

Severe hepatic and/or renal insufficiency [+12]

Status: Not yet recruiting

Establishment of Disease Characteristics and a Chinese Medicine Prognosis Risk Model Based on a Large-Scale Database After Coronary Revascularization

This study aims to develop a risk prediction model for patients who have undergone coronary revascularization (such as stent placement or bypass surgery). After these procedures, some patients still experience heart-related problems like chest pain, heart attack, or rehospitalization. This study will enroll 600 patients from multiple hospitals in China and follow them for 12 months. At enrollment and at 12, 24, 36, and 48 weeks after surgery, researchers will collect clinical information (including traditional Chinese medicine symptoms, blood tests, heart imaging) and biological samples (blood and tongue coating). Using artificial intelligence, the study will build a predictive model that combines Western medical data with traditional Chinese medicine characteristics. The goal is to better identify patients at higher risk of future heart events, so that personalized prevention and management can be provided. The study does not involve any experimental treatment or intervention - it is purely observational.

Participants needed: 600
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Liu QiangUpdated: May 29, 2026Duration: 12 Months
Eligibility criteria

Diagnosis of coronary artery disease with prior coronary revascularization (PCI... [+2]

Malignant arrhythmias, severe heart failure, myocardial disease, or structural h... [+4]

Status: Not yet recruiting

Baduanjin Intervention in Clinical Studies After Coronary Revascularization Surgery

1. To evaluate the efficacy and safety of the Baduanjin exercise programme in patients following coronary revascularisation surgery; 2. To develop a traditional Chinese medicine (TCM) rehabilitation protocol and evaluation system for patients following coronary revascularisation surgery; 3. To clarify the advantages of TCM rehabilitation in the post-operative management of coronary revascularisation surgery and to provide high-level evidence-based medical evidence for TCM rehabilitation protocols.

Participants needed: 310
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Liu QiangUpdated: May 27, 2026
Eligibility criteria

Participants who meet the diagnostic criteria for coronary heart disease [+4]

Subjects with severe hepatic or renal impairment [+12]

Status: Not yet recruiting

Nursing Intervention for Adaptation After Myocardial Revascularization

Introduction: Myocardial revascularization is an essential procedure for patients with cardiovascular disease. Its recovery in the outpatient setting involves significant challenges for both the patient and the caregiver. This recovery phase may generate physical, emotional, and psychological complications that require an effective adaptation process of the patient-caregiver dyad to ensure successful recovery and improved quality of life. Objective: To evaluate the preliminary effectiveness of a nursing intervention aimed at improving adaptation in the patient-caregiver dyad during the outpatient postoperative period following myocardial revascularization, compared with usual care, in Bucaramanga during the period 2026-2027. Materials and Methods: A pilot randomized controlled trial will be conducted to develop and evaluate a novel nursing intervention aimed at promoting adaptation in patients undergoing outpatient postoperative myocardial revascularization and their caregivers. The intervention will be designed and its feasibility, acceptability, and preliminary effectiveness will be assessed. Data analysis will be performed using descriptive and inferential statistical methods, considering the distribution and behavior of the data. Expected Results: The study is expected to assess the preliminary effectiveness of the proposed intervention through the integration of theoretical and empirical components.

Participants needed: 40
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Universidad de la SabanaUpdated: May 8, 2026Locations: 1
Eligibility criteria

Adults aged 18 years or older who have undergone myocardial revascularization su... [+4]

Patients presenting severe postoperative complications, such as deep surgical si... [+4]

Status: Not yet recruiting

Disease Characteristics of R-CAD

The present case-control study is designed to investigate the disease characteristics of rapidly progressive coronary artery disease (R-CAD) by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between patients in the case group (approximately 34 patients with R-CAD) and those in the control group (approximately 18 patients with non-rapidly progressive coronary artery disease \[NR-CAD\]).

Participants needed: 52
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Peking Union Medical College HospitalUpdated: Nov 28, 2025
Eligibility criteria

18 years of age or older, male or female. [+13]

Receiving immunosuppressive therapy within 6 months. [+11]